Alpha Tau Medical Ltd Cl A (DRTS) Stock Price, Quote & News

Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 577 4115

Website: www.alphatau.com

Address:

Kiryat HaMada St. 5, Jerusalem, Israel

OnlyGB Apr. 21 at 10:23 AM

$DRTS in the low 8’s actually means that $10 is not so far away. One announcement of a commercial agreement. One jaw dropping set of Pancreatic cancer results. One game changer for GBM. One sniff of an M&A deal. And just like that, $10 will be in the rear view mirror.

1 · Reply

Jessypenny Apr. 21 at 9:03 AM

$DRTS With pancreatic cancer being one of the toughest nuts to crack in oncology, the DDW presentation puts DRTS in the center of the GI and hepatology world. We aren't just trading a ticker, we're trading a potential shift in how solid tumors are treated.

0 · Reply

kareem1988 Apr. 21 at 8:49 AM

$DRTS compressing just below $8.50, a level it's tested multiple times. Volume is still low, short interest near zero, DDW catalyst May 2. Chart looks like a coiled spring heading into a binary event. Just saying.

1 · Reply

JohnStocksNY Apr. 20 at 8:04 PM

$DRTS Nice close everyone!

1 · Reply

67StingRay Apr. 20 at 4:46 PM

$DRTS Remember the downgrade, lol

1 · Reply

Merlintrader Apr. 20 at 2:41 PM

$DRTS

1 · Reply

Nardwuar_ Apr. 20 at 2:28 PM

$IBRX $DRTS who’s seeing $10 first? 👀

3 · Reply

Witspro Apr. 20 at 2:09 PM

$DRTS how big is this? Elaborate

1 · Reply

chinesechickenballz Apr. 20 at 1:48 PM

$DRTS

1 · Reply

Hart4Charts Apr. 20 at 1:38 PM

$DRTS microcap volatility, watch tape closely

1 · Reply

Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026

Mar 16, 2026, 10:02 AM EDT - 5 weeks ago

Alpha Tau to Present at Sidoti March Virtual Small Cap Conference

Mar 9, 2026, 4:02 PM EDT - 6 weeks ago

Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update

Feb 24, 2026, 8:51 PM EST - 7 weeks ago

HekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRT

Feb 24, 2026, 9:00 AM EST - 7 weeks ago

Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer

Feb 3, 2026, 12:37 PM EST - 2 months ago

Altamirano PLLC Issues Investor Notice on Inspired Healthcare Capital (IHC) Chapter 11 Bankruptcy Filing

Jan 29, 2026, 9:00 AM EST - 2 months ago

Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead

Jan 6, 2026, 9:00 AM EST - 3 months ago

Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study

Jan 5, 2026, 9:00 AM EST - 3 months ago

Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)

Dec 9, 2025, 9:00 AM EST - 4 months ago

Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University

Nov 20, 2025, 4:05 PM EST - 5 months ago

Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 11, 2025, 8:30 AM EST - 5 months ago

Alpha Tau to Participate at Jefferies Global Healthcare Conference in London

Oct 21, 2025, 8:30 AM EDT - 6 months ago

Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness

Oct 17, 2025, 10:04 AM EDT - 6 months ago

Altamirano PLLC Issues Notice to Inspired Healthcare Capital (IHC) Investors on Recovery Options

Sep 2, 2025, 8:30 AM EDT - 8 months ago

Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial

Aug 27, 2025, 8:30 AM EDT - 8 months ago

Alpha Tau to Participate in Five September Investor Conferences

Aug 11, 2025, 4:02 PM EDT - 9 months ago

Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 25, 2025, 9:04 AM EDT - 9 months ago

Revival Healthcare Capital Announces Strategic Partnership to Accelerate External Innovation in Robotics With up to $458 Million Joint Investment With Olympus Into Co-Founded New Company Swan EndoSurgical

May 19, 2025, 4:01 PM EDT - 1 year ago

Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025, 4:01 PM EDT - 1 year ago

Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors

May 6, 2025, 8:30 AM EDT - 1 year ago

Alpha Tau to Participate in May Investor Conferences

Apr 28, 2025, 9:00 AM EDT - 1 year ago

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

ORMP

Apr 28, 2025, 9:00 AM EDT - 1 year ago

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

ORMP

Apr 2, 2025, 8:30 AM EDT - 1 year ago

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma

Mar 12, 2025, 4:02 PM EDT - 1 year ago

Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update

Feb 24, 2025, 8:30 AM EST - 1 year ago

Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification

Jan 27, 2025, 9:00 AM EST - 1 year ago

Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

Dec 18, 2024, 8:30 AM EST - 1 year ago

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

Dec 17, 2024, 9:00 AM EST - 1 year ago

Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

Dec 11, 2024, 8:30 AM EST - 1 year ago

Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 6, 2024, 8:30 AM EST - 1 year ago

Alpha Tau to Participate in Ladenburg's Oncology Innovators & Investors Symposium

Nov 13, 2024, 8:30 AM EST - 1 year ago

Alpha Tau to Participate in Citi's 2024 Global Healthcare Conference and Piper Sandler's 36th Annual Healthcare Conference

Oct 21, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Announces Acceptance Into FDA's Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Treats First Patient with Recurrent Lung Cancer

Sep 20, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC

Aug 22, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Conference

Aug 14, 2024, 4:02 PM EDT - 1 year ago

Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Jun 25, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers

May 21, 2024, 8:45 AM EDT - 2 years ago

Alpha Tau to Present at the Jefferies Global Healthcare Conference

May 20, 2024, 4:01 PM EDT - 2 years ago

Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 13, 2024, 8:30 AM EDT - 2 years ago

Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer

May 6, 2024, 8:30 AM EDT - 2 years ago

Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow

Mar 25, 2024, 8:50 AM EDT - 2 years ago

Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit

Mar 7, 2024, 4:01 PM EST - 2 years ago

Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update

Feb 26, 2024, 8:30 AM EST - 2 years ago

Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference

Dec 20, 2023, 9:15 AM EST - 2 years ago

Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 29, 2023, 8:30 AM EST - 2 years ago

Alpha Tau to Participate in Sidoti Small-Cap Conference

Nov 28, 2023, 8:30 AM EST - 2 years ago

Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer

Nov 20, 2023, 8:30 AM EST - 2 years ago

Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer

Nov 16, 2023, 4:30 PM EST - 2 years ago

Alpha Tau Medical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

OnlyGB Apr. 21 at 10:23 AM

1 · Reply

Jessypenny Apr. 21 at 9:03 AM

0 · Reply

kareem1988 Apr. 21 at 8:49 AM

1 · Reply

JohnStocksNY Apr. 20 at 8:04 PM

$DRTS Nice close everyone!

1 · Reply

67StingRay Apr. 20 at 4:46 PM

$DRTS Remember the downgrade, lol

1 · Reply

Merlintrader Apr. 20 at 2:41 PM

$DRTS

1 · Reply

Nardwuar_ Apr. 20 at 2:28 PM

$IBRX $DRTS who’s seeing $10 first? 👀

3 · Reply

Witspro Apr. 20 at 2:09 PM

$DRTS how big is this? Elaborate

1 · Reply

chinesechickenballz Apr. 20 at 1:48 PM

$DRTS

1 · Reply

Hart4Charts Apr. 20 at 1:38 PM

$DRTS microcap volatility, watch tape closely

1 · Reply

Joshsim123 Apr. 20 at 12:00 PM

$DRTS is seeing some serious momentum! The stock is holding strong in the green, gaining 17.4% over the last two weeks. This should continue with the DDW convention just around the corner.

1 · Reply

Jessypenny Apr. 20 at 10:36 AM

Most people miss the significance: $DRTS was selected for an oral podium presentation at DDW on May 2nd. This isn't just a poster in a hallway it’s a spotlight on the pancreatic data. 2 weeks of green is just the market heating up for the prestige.

0 · Reply

JohnStocksNY Apr. 20 at 10:31 AM

$DRTS even when the macro is shaky we get a nice green light to open our eyes to. It’s gonna be a great week getting closer to DDW and the new Pancreatic Cancer data!

2 · Reply

kareem1988 Apr. 20 at 10:24 AM

All eyes on $DRTS as we head into DDW! The momentum is building fast with two straight weeks of serious strength. The market is finally waking up to $DRTS potential.

2 · Reply

JohnStocksNY Apr. 20 at 10:22 AM

$DRTS Got a contest going between the Technical Analysis and the Fundamentals which is getting more attention

2 · Reply

OnlyGB Apr. 20 at 9:54 AM

$DRTS is looking at a great setup this week. Racing closer to the May 2nd Pancreatic Cancer results. Let’s front run the newbies!!!

2 · Reply

JohnStocksNY Apr. 20 at 6:34 AM

$DRTS New trading week is upon us, IYKYK it’s coming and you’ll be accumulating no matter the price action

2 · Reply

Doozio Apr. 19 at 3:48 PM

Out of the bahhhtom of da base $JXN is ready to throw moar $DRTS ONTA 🐒🍌🧠⏰♾️

2 · Reply

Merlintrader Apr. 18 at 6:01 PM

$DRTS Alpha Tau Medical, Japan Approval, Pancreatic DDW 2026, GBM Optionality and a Technical Setup That Finally Looks Awake https://www.merlintrader.com/alpha-tau-medical-april2026-deepdive/

4 · Reply

kareem1988 Apr. 17 at 1:02 PM

Will $DRTS run the table this week? Momentum is real, lets finish with a perfect green week!

2 · Reply

JohnStocksNY Apr. 17 at 12:50 PM

$DRTS How we’ve been waking up to the pre market this week

1 · Reply

Jessypenny Apr. 17 at 9:53 AM

$DRTS just touched 8! The breakout we’ve been waiting for is happening. Volume is picking up and the momentum is real. Blue skies ahead!

1 · Reply

Market Cap	681.11M
Revenue (ttm)	0.00
Net Income (ttm)	-42.63M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.08

Volume	246,900
Avg Vol	274,698
Day's Range	N/A - N/A
Shares Out	84.82M
Stochastic %K	84%
Beta	1.04
Analysts	Sell
Price Target	$9.67